Physician profile
Roberto Salcedo
NPI 1417930959
$84,485.37
in general payments reported to CMS, 2019-2025
57 companies · $8,906 in 2025
The $8,906 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $7,511 · 2021: $14K · 2022: $11K · 2023: $12K · 2024: $18K · 2025: $8,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $15K · Education: $44.47 · Travel and Lodging: $3.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,062.81 |
| Food and Beverage | $14,721.40 |
| Education | $44.47 |
| Travel and Lodging | $3.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $54,976.76 | 2019-2025 | |
| Catalyst Pharmaceuticals, INC. | $3,866.62 | 2019 | |
| Biogen, INC. | $2,420.43 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Ucb, INC. | $2,401.23 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $2,091.94 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Genentech USA, INC. | $1,483.15 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $1,463.79 | 2019-2025 | |
| Abbvie INC. | $1,189.49 | 2021-2025 | Ubrelvy, Qulipta |
| Mdd US Operations, LLC | $972.66 | 2019-2025 | Gocovri, Gocovri |
| Amgen INC. | $926.35 | 2019-2025 | Aimovig, Uplizna |
| Celgene Corporation | $884.02 | 2019-2025 | Zeposia |
| Argenx US, INC. | $843.94 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $822.63 | 2019-2025 | Nuplazid, Daybue |
| Neurelis, INC. | $757.02 | 2021-2025 | Valtoco |
| Lilly USA, LLC | $741.87 | 2019-2024 | Emgality, Reyvow, Amyvid |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Salcedo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.